U.S. Office REITs Stock News

NYSE:PBH
NYSE:PBHPharmaceuticals

Has Prestige Consumer Healthcare (PBH) Fallen Too Far After Its 37% One-Year Share Price Drop?

If you are wondering whether Prestige Consumer Healthcare is attractively priced or just a value trap, the stock's recent performance and fundamentals give you plenty to weigh up. The share price recently closed at US$54.59, with returns of a 3.1% decline over 7 days, a 1.9% decline over 30 days, a 10.8% decline year to date, and a 37.3% decline over the last year, while the 3 year and 5 year returns stand at a 6.4% decline and 12.3% respectively. Recent coverage has focused on Prestige...
NasdaqGS:PFG
NasdaqGS:PFGInsurance

Is It Time To Reassess Principal Financial Group (PFG) After Strong Multi Year Share Price Gains

Investors may be asking whether Principal Financial Group at around US$100 per share is offering fair value or a potential mispricing opportunity right now. The stock has recently seen a 0.9% decline over 7 days, compared with stronger returns of 9.9% over 30 days, 11.9% year to date, 31.8% over 1 year, 62.3% over 3 years and 83.4% over 5 years. Recent coverage has focused on how investors are reassessing insurers like Principal Financial Group in light of broader sector trends and shifting...
NasdaqGS:CGON
NasdaqGS:CGONBiotechs

CG Oncology (CGON) Deep LTM Losses Test Bullish Late Stage Pipeline Narratives

CG Oncology (CGON) has just closed out FY 2025 with Q4 revenue of US$2.3 million and a basic EPS loss of US$0.52, alongside a net income loss of US$41.3 million, as the company continues to invest heavily in its pipeline. Over the last twelve months, revenue has summed to US$4.0 million and basic EPS has come in at a loss of US$2.08. This gives investors a clear view of a business that is still in a development phase and running with intentionally thin margins while it pushes its late stage...
NYSE:NVST
NYSE:NVSTMedical Equipment

Is It Time To Reassess Envista Holdings (NVST) After Its Recent Share Price Pullback

If you are wondering whether Envista Holdings at US$24.29 offers good value or is already fully priced, the recent share performance gives you a useful starting point. The stock has pulled back 6.4% over the last 7 days and 4.0% over the last 30 days. It sits 12.0% higher year to date and 36.7% above where it was a year ago, while the 3 year and 5 year returns of 26.7% and 44.7% highlight a tougher longer term journey. Recent coverage has focused on Envista Holdings as a dental equipment and...
NYSE:UI
NYSE:UICommunications

Ubiquiti (UI) Earnings Surge And 29.9% Margin Spark Debate On Valuation Premium

Ubiquiti (UI) has put up another big quarter, with Q2 2026 revenue of US$814.9 million and basic EPS of US$3.86, while trailing 12 month EPS sits at US$14.69 on revenue of about US$3.0 billion and earnings growth over that period is described as a 99.7% jump. The company has seen quarterly revenue move from US$599.9 million and EPS of US$2.26 in Q2 2025 to US$814.9 million and EPS of US$3.86 in Q2 2026, and trailing 12 month net profit margin is now stated at 29.9% versus 20.7% a year...
NYSE:MUR
NYSE:MUROil and Gas

Is Murphy Oil (MUR) Still Attractive After An 88% One Year Share Price Surge

If you are wondering whether Murphy Oil at around US$38.27 is offering value or just riding momentum, the recent share performance gives you plenty to think about. The stock has seen a 1 year return of 88.2% and is up 17.8% year to date, despite shorter term pullbacks with a 7 day return showing an 8.4% decline and a 30 day return showing a 10.5% decline. Recent coverage has focused on Murphy Oil as part of broader conversations around US oil and gas stocks, with attention on how producers...
NasdaqCM:OCGN
NasdaqCM:OCGNBiotechs

Ocugen (OCGN) Is Down 16.8% After Convertible Notes Deal Extends Cash Runway - What's Changed

In early May 2026, Ocugen reported first-quarter revenue of US$1.53 million alongside a net loss of US$19.18 million, while also closing a US$115 million private offering of 6.75% Convertible Senior Notes due 2034 and using about US$32.7 million to retire its Avenue loan. These updates both highlight Ocugen’s ongoing cash burn and materially improve its liquidity profile, with management indicating the new financing extends the company’s cash runway and supports continued advancement of its...
NasdaqGS:SLDE
NasdaqGS:SLDEInsurance

Slide Insurance Enters California As Valuation Gap And Growth Risks Stand Out

Slide Insurance Holdings (NasdaqGS:SLDE) has entered the California market with a new excess and surplus lines residential property insurance program. The company has written its first California policy, marking the start of its operations in one of the largest U.S. property insurance markets. For investors watching property insurers, California represents a complex and heavily scrutinized market, especially for residential coverage. By using an excess and surplus lines structure, Slide...
NasdaqGS:XRAY
NasdaqGS:XRAYMedical Equipment

Is Dentsply Sirona (XRAY) Now Offering Value After A 28% One Year Share Price Slide

If you are wondering whether DENTSPLY SIRONA stock is starting to look interesting at current levels, its recent price and valuation signals give you a lot to think about. The share price sits at US$10.96 after a 6.7% decline over the last week, a 4.9% decline over the last month and a 28.5% decline over the last year, which may change how you view both its risk and potential reward. Recent coverage around DENTSPLY SIRONA has focused on its position within the medical equipment space and how...
NYSE:MIAX
NYSE:MIAXCapital Markets

Is It Too Late To Consider Miami International Holdings (MIAX) After Recent Share Price Gains?

If you are wondering whether Miami International Holdings at around US$49.77 is priced attractively or not, the key question is how that tag compares with what the business could reasonably be worth. Over shorter periods, the stock has been active, with returns of 7.1% over the last 7 days, 20.5% over the last 30 days and 14.0% year to date, which hints that expectations and perceived risk are shifting. Recent coverage has focused on Miami International Holdings as part of broader...
NYSE:SES
NYSE:SESElectrical

SES AI Shifts Toward Defense And Storage With New Contracts And AI

SES AI (NYSE:SES) has converted its South Korea facility to produce NDAA-compliant drone battery cells for defense customers. The company signed a multi-year, $20 million distribution agreement with ATG EPower for North American energy storage systems. SES AI is applying AI tools to optimize defense-focused battery products, expanding its use of the technology beyond R&D. SES AI, trading at about $0.921 per share, is shifting focus beyond long-cycle EV battery development toward products...
NasdaqGS:SLDP
NasdaqGS:SLDPAuto Components

Solid Power (SLDP) Valuation Check As Electrolyte Commercialization And Partnerships Progress

Solid Power (SLDP) is in focus after reporting first quarter 2026 results alongside progress on its electrolyte commercialization plans, giving you fresh numbers and project updates to weigh against the current share price. See our latest analysis for Solid Power. Solid Power’s recent earnings update, electrolyte progress with SK On and Samsung SDI, and funding raise come after a volatile period, with a 1-day share price return of negative 12.71% and a 1-year total shareholder return of very...
NasdaqGS:NTSK
NasdaqGS:NTSKSoftware

Netskope Unveils AgentSkope As Investors Weigh AI Automation Prospects

Netskope (NasdaqGS:NTSK) has introduced AgentSkope, an AI-driven agentic operations platform for automating security and network workflows. The new platform brings a suite of AI-powered agents designed to handle routine and complex operational tasks for security and network teams. This launch adds a fresh product to Netskope's portfolio in automated cybersecurity operations, an area where many enterprises are seeking more efficiency. Netskope trades at $11.4, with the stock showing a 14.5%...
NasdaqCM:CORT
NasdaqCM:CORTPharmaceuticals

Corcept’s ALS Survival Signal Reframes Cortisol Modulation And Growth Outlook

Corcept Therapeutics reported long term survival data from its DAZALS Phase 2 trial of dazucorilant in ALS. Patients receiving 300 mg daily experienced an 87% reduction in risk of death at two years. The trial did not meet its primary functional endpoint, but the survival benefit attracted attention at the ENCALS 2025 meeting. For investors tracking NasdaqCM:CORT, this new ALS data adds another layer to the story around Corcept Therapeutics beyond its core cortisol modulation work. The...
NYSE:RBA
NYSE:RBACommercial Services

Is It Too Late To Reassess RB Global (RBA) After Its Recent Share Price Surge?

Investors may be wondering if RB Global at around US$103 a share is still offering value or if most of the upside is already priced in. The stock has been fairly steady year to date, with a 0.1% return. However, that headline number masks a 5.8% gain over the past month, a small 0.8% slip in the last week, and a return of 97.8% over three years and 85.2% over five years. Recent coverage has focused on RB Global's role in the Commercial Services sector and how investors are reacting to its...